Real-world efficacy of nanoliposomal irinotecan in patients with advanced pancreatic cancer.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
58 patients with advanced pancreatic adenocarcinomas who received Nal-Iri combined with fluorouracil and folinic acid in three medical centers between March 2020 and September 2022 were included.
I · Intervention 중재 / 시술
gemcitabine-based therapy
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[TRIAL REGISTRATION] NCT06006728, Registration Date: August 23, 2023. [SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-025-15346-8.
[BACKGROUND] In the randomized NAPOLI-1 trial, nanoliposomal irinotecan (Nal-Iri) combined with fluorouracil and folinic acid provided considerable survival increase for patients with metastatic pancr
APA
Decraecker M, Le Joncour S, et al. (2025). Real-world efficacy of nanoliposomal irinotecan in patients with advanced pancreatic cancer.. BMC cancer, 26(1), 3. https://doi.org/10.1186/s12885-025-15346-8
MLA
Decraecker M, et al.. "Real-world efficacy of nanoliposomal irinotecan in patients with advanced pancreatic cancer.." BMC cancer, vol. 26, no. 1, 2025, pp. 3.
PMID
41316032 ↗
Abstract 한글 요약
[BACKGROUND] In the randomized NAPOLI-1 trial, nanoliposomal irinotecan (Nal-Iri) combined with fluorouracil and folinic acid provided considerable survival increase for patients with metastatic pancreatic ductal adenocarcinomas who had received gemcitabine-based therapy. However, patients included in clinical trials often differ from those encountered in practice. A real-world study was required to assess the efficacy and safety of Nal-Iri in patients with poor prognoses for whom quality of life preservation was essential.
[METHODS] We conducted an observational, retrospective national multicenter phase 4 study of patients with advanced pancreatic cancers treated using Nal-Iri combined with fluorouracil and folinic acid in clinical practice. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan–Meier method. We used a nomogram validated from a concordance index of eight clinicobiological variables to predict OS.
[RESULTS] A total of 58 patients with advanced pancreatic adenocarcinomas who received Nal-Iri combined with fluorouracil and folinic acid in three medical centers between March 2020 and September 2022 were included. The median duration of Nal-Iri treatment was 3.6 (range 1.9–8.8) months. The median follow-up time from the start of first-line treatment was 26.2 (16.5–44.8) months. Of all patients, 20.7% received Nal-Iri in a second-line setting, but most ( = 37 patients; 63.8%) received Nal-Iri in a third-line setting. Forty-two patients (72.4%) had previously been treated with irinotecan. The median OS from the time of Nal-Iri initiation was 6.0 (2.6–13.1) months, and the median PFS was 2.1 (1.7–2.6) months. Patients who received Nal-Iri in a second-line setting exhibited significantly better OS than patients who received Nal-Iri in a third-line setting or later ( < 10). Patients who had previously received irinotecan exhibited significantly lower OS compared with patients who were irinotecan-naïve ( < 10).Our nomogram demonstrated excellent prediction of 6-month and 1-year survivals ( < 10 ).
[CONCLUSIONS] Nal-Iri combined with fluorouracil and folinic acid was particularly effective in second-line settings and irinotecan non-pre-treated patients. The nomogram demonstrated excellent prediction of survival under real-world conditions.
[TRIAL REGISTRATION] NCT06006728, Registration Date: August 23, 2023.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-025-15346-8.
[METHODS] We conducted an observational, retrospective national multicenter phase 4 study of patients with advanced pancreatic cancers treated using Nal-Iri combined with fluorouracil and folinic acid in clinical practice. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan–Meier method. We used a nomogram validated from a concordance index of eight clinicobiological variables to predict OS.
[RESULTS] A total of 58 patients with advanced pancreatic adenocarcinomas who received Nal-Iri combined with fluorouracil and folinic acid in three medical centers between March 2020 and September 2022 were included. The median duration of Nal-Iri treatment was 3.6 (range 1.9–8.8) months. The median follow-up time from the start of first-line treatment was 26.2 (16.5–44.8) months. Of all patients, 20.7% received Nal-Iri in a second-line setting, but most ( = 37 patients; 63.8%) received Nal-Iri in a third-line setting. Forty-two patients (72.4%) had previously been treated with irinotecan. The median OS from the time of Nal-Iri initiation was 6.0 (2.6–13.1) months, and the median PFS was 2.1 (1.7–2.6) months. Patients who received Nal-Iri in a second-line setting exhibited significantly better OS than patients who received Nal-Iri in a third-line setting or later ( < 10). Patients who had previously received irinotecan exhibited significantly lower OS compared with patients who were irinotecan-naïve ( < 10).Our nomogram demonstrated excellent prediction of 6-month and 1-year survivals ( < 10 ).
[CONCLUSIONS] Nal-Iri combined with fluorouracil and folinic acid was particularly effective in second-line settings and irinotecan non-pre-treated patients. The nomogram demonstrated excellent prediction of survival under real-world conditions.
[TRIAL REGISTRATION] NCT06006728, Registration Date: August 23, 2023.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-025-15346-8.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Current Systemic Treatment Options for Advanced Pancreatic Cancer-An Overview Article.
- Development and validation of a novel nomogram model for predicting postoperative survival of T4N0M0 NSCLC: a population-based survival analysis.
- Clinical Characteristics and Prognostic Prediction of Secondary Solid Malignancies in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
- Impact of Skeletal Muscle-related Parameters on Survival in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine plus Nab-paclitaxel as First-line Chemotherapy.
- Carbon ion radiotherapy optimization techniques for pancreatic cancer: accounting for the effect of bowel gas variation.
- Independent Risk Factors and Nomogram-Based Prediction of Pulmonary Fungal Infection in Lung Cancer Inpatients: A Single-Center Retrospective Study.